Bristol Myers Squibb stock trades around recent lows as Revlimid erosion weighs on 2024 outlook

Bristol Myers Squibb stock is trading near the lower end of its twelve month range as investors digest the impact of Revlimid patent expiry on 2024 results and assess the ramp up of newer oncology and immunology medicines. According to data from a major US exchange as of 22 July 2026, the company carried a market capitalization in the tens of billions of US dollars, placing it firmly among the larger components of the S&P 500 healthcare cohort.

Revenue of about $45 billion in 2023

In its most recent full fiscal year 2023, Bristol Myers Squibb reported total revenue in the region of $45 billion, according to figures the company has published in its annual investor materials on its own corporate site. Within that total, the portfolio remained highly concentrated, with a handful of major therapies accounting for the bulk of sales, and investors paid close attention to how much of the group top line still depended on legacy blockbusters facing rising competition.

One of the clearest examples is Revlimid, the blood cancer therapy that has long been one of the company’s largest products. In the period around 2022 and 2023, management highlighted that Revlimid revenue was now declining year on year as generic competition expanded. In one recent quarterly period, Revlimid sales fell by a double digit percentage compared with the prior year, illustrating how the erosion of a single blockbuster can create a substantial headwind for overall group revenue even when the new product portfolio is growing.

To counter this headwind, Bristol Myers Squibb has emphasized the contribution from its so called new product portfolio, a group of recently launched therapies in oncology, hematology, and cardiovascular disease. Across 2023 and into 2024, this newer group of medicines collectively generated several billions of dollars in annualized revenue, and management has repeatedly described a target for these new products to deliver more than $10 billion in revenue by the middle of the decade. That quantified ambition is central to the equity story because investors want to see concrete numbers showing the transition from dependence on Revlimid, Eliquis co promotion economics, and Opdivo toward a broader base of future growth drivers.

New portfolio growth offsets a double digit Revlimid decline

The company’s quarterly updates over the past year underline how that transition is progressing in numerical terms. In one recent quarter during 2023, Bristol Myers Squibb reported that its new product portfolio grew revenue by more than 50 percent year on year, while Revlimid revenue declined by more than 30 percent versus the same period in the previous year. That combination meant that, although the total company revenue line was roughly flat or slightly down on a reported basis, the internal mix of revenue shifted meaningfully toward the newer assets that are expected to drive growth beyond this decade.

For example, cardiovascular therapy sales, including contributions from newer treatments, added hundreds of millions of dollars in quarterly revenue in 2023, helping to balance pressure in hematology. Similarly, oncology assets in immunotherapy and targeted therapies collectively increased their revenue contribution compared with the prior year period, even as one or two more mature oncology brands plateaued. By presenting these comparative numbers against prior quarters and prior years, the company aims to demonstrate that, while individual drugs like Revlimid are on a clear downward path, the newer medicines are scaling quickly enough to narrow the gap.

Operating profitability has inevitably been affected by this shifting mix. As Revlimid and other mature therapies decline, their historically high margins are replaced by newer products that initially carry higher launch and commercialization costs. In the 2023 reporting period, Bristol Myers Squibb still generated several billions of dollars in net income, but the margin profile reflected the investment phase for many launches. Management has provided medium term guidance that contemplates continued investment in research, development, and commercial infrastructure while free cash flow remains robust enough to support the dividend.

Representative product Opdivo extends across indications

Among the better known medicines in the Bristol Myers Squibb portfolio, the immuno oncology drug Opdivo has continued to play a central commercial and strategic role. Opdivo has secured approvals in a wide range of cancer indications, and the company has reported that annual sales for the therapy have reached many billions of dollars in recent years. That places Opdivo among the top oncology brands worldwide and underscores its role as a pillar of the company’s revenue base alongside cardiovascular medicines.

In recent quarterly updates, management has highlighted that Opdivo sales have grown year on year in several key markets thanks to label expansions and increased penetration in earlier lines of therapy. By comparing recent quarter revenue levels for Opdivo with those reported a year earlier, investors can see that the drug’s growth has helped mitigate some of the impact from declining Revlimid sales, even if it has not been sufficient on its own to deliver strong top line growth at the group level. The company continues to invest in clinical trials designed to extend Opdivo into additional indications and combinations, which, if successful, could sustain its revenue contribution well into the next decade.

Stock valuation reflects patent cycle transition

For investors observing Bristol Myers Squibb stock on the New York Stock Exchange, the share price over the last year has traded in a band that reflects both the risks tied to patent expiries and the potential embedded in the new product portfolio. The fact that the market capitalization as of late July 2026 remains in the large cap range shows that the equity market continues to assign substantial value to the company’s pipeline and diversified portfolio, even if the stock trades below earlier highs seen before the full onset of Revlimid erosion.

Analysts following large cap US pharmaceuticals often compare valuation multiples such as forward price to earnings or enterprise value to expected 2025 and 2026 revenue across a peer group that includes other major US and European drug makers. In that context, Bristol Myers Squibb frequently screens at a discount to some faster growing peers whose revenue is less exposed to immediately expiring patents. The numerical gap in valuation multiples, sometimes amounting to several turns of price to earnings, represents in part a market judgment on how effectively Bristol Myers Squibb will convert its clinical pipeline and recently launched products into durable, growing revenue streams that can replace and exceed the billions of dollars of annual sales lost from Revlimid and other mature therapies.

At the same time, the company’s dividend yield, derived by dividing its annual cash dividend per share by the prevailing share price, has tended to be higher than that of some peers whose shares trade on richer growth expectations. The sustainability of that dividend ultimately depends on the company’s ability to maintain strong cash generation while investing adequately in research and commercialization, a balance that the management team has addressed in its capital allocation commentary during recent financial updates.

Key medicines beyond Opdivo

Beyond Opdivo and Revlimid, Bristol Myers Squibb markets a broad range of therapies in oncology, hematology, immunology, and cardiovascular disease. These include combination regimens in cancer, oral therapies for immune mediated conditions, and cardiovascular treatments that address high unmet medical need. The company’s strategy has been to build depth in chosen therapeutic areas rather than spread resources across too many disparate fields, which is reflected in the concentration of its late stage pipeline and recent regulatory submissions.

From a numerical standpoint, management has pointed to the combined revenue potential of its launched and late stage pipeline products as a key justification for ongoing investment. When adding together the actual 2023 revenue from the new product portfolio and the projected contributions from late stage candidates, the company has described an aggregate figure in the tens of billions of dollars for the late decade period, underscoring that the patent cliff for Revlimid, while significant, is not the sole determinant of Bristol Myers Squibb’s long term earnings power.

Stock level and trading venue

Bristol Myers Squibb stock is listed on the New York Stock Exchange and trades in US dollars under a ticker symbol that is widely followed by both institutional and retail investors. As of 22 July 2026, the shares changed hands at a price point in the tens of dollars, leaving them closer to the twelve month low than to the corresponding high, a configuration that reflects the market’s cautious stance on near term earnings growth. That share price, combined with the number of shares outstanding reported in recent filings, is consistent with the previously mentioned large cap market capitalization figure.

For investors, the interaction between the share price, the dividend yield, and the company’s ability to grow revenue from its new product portfolio versus the speed of decline in legacy products will remain central. If, over the next several reported quarters, revenue numbers show that new products are steadily increasing their share of the total and that total company revenue is returning to growth versus prior years, there would be numerical evidence that the transition beyond the Revlimid cliff is succeeding. Conversely, if reported figures show that declines in mature drugs are outpacing gains from new launches, the stock valuation could continue to reflect a more cautious outlook.